---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-215721"
form_type: "8-K"
ticker: "NTLA"
cik: "0001652130"
company_name: "Intellia Therapeutics, Inc."
filed_at: "2026-05-11T23:59:59+00:00"
generated_at: "2026-05-14T18:43:43.822455+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Intellia Q1 loss narrows; Phase 3 HAE data positive, rolling BLA initiated

## Summary
- Net loss $96.2M vs $114.3M YoY; revenue $15.0M (down from $16.6M).
- Phase 3 HAELO topline: lonvo-z reduced HAE attacks 87% vs placebo (p<0.0001); mean monthly attack rate 0.26 vs 2.10.
- Rolling BLA for lonvo-z initiated; completion H2 2026 for potential US launch H1 2027.
- Cash $517.2M at Mar 31; April offering raised ~$207M gross; runway into 2028 excluding lonvo-z revenue.
- FDA lifted clinical holds on nex-z Phase 3 trials (MAGNITUDE/MAGNITUDE-2); patient screening resumed.

## SEC filing metadata
- accession: 0001193125-26-215721
- form_type: 8-K
- ticker: NTLA
- cik: 0001652130
- company_name: Intellia Therapeutics, Inc.
- filed_at: 2026-05-11T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1652130/000119312526215721/0001193125-26-215721-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1652130/000119312526215721/ntla-20260511.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-215721
- JSON: https://secwatch.observer/filing/0001193125-26-215721.json
- Plain text: https://secwatch.observer/filing/0001193125-26-215721.txt

## Source-grounded claims
- claim_id: 73d6c343e00d3979daaed2ddb90a30b54e097529
  claim: Intellia Therapeutics, Inc. reported the first quarter ended March 31, 2026 results: revenue $15.0 million. Guidance reaffirmed.
  evidence_excerpt: commercial launch for HAE in the first half of 2027. This guidance excludes all potential commercial revenues from lonvo-z. • Collaboration Revenue : Collaboration revenue was $15.0 million for the first quarter of 2026, compared to $16.6 million for the first quarter of 2025. • R&D Expenses : Research and development (R&D) expenses were $80.7 million for the first
  evidence_url: https://www.sec.gov/Archives/edgar/data/1652130/000119312526215721/0001193125-26-215721-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.